Related Experiment Video

Updated: Jun 13, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

[Nevirapine and cardiovascular risk]

J-J Parienti1, R Verdon

  • 1Service des Maladies Infectieuses et Tropicales, CHU Côte-de-Nacre, avenue de la Côte-de-Nacre, 14033 Caen, France. parienti-jj@chu-caen.fr

Medecine Et Maladies Infectieuses
|May 4, 2010
PubMed

Insights

Nevirapine, an antiretroviral treatment, may offer cardiovascular benefits by improving HDL-c lipid profiles through increased apolipoprotein A1 production. This suggests a potentially lower cardiovascular risk for HIV patients using nevirapine.

Area of Science:

  • HIV/AIDS management
  • Cardiovascular disease in HIV
  • Pharmacological interventions

Context:

  • Long-term adverse effects of antiretroviral therapy (ART) are a significant concern for HIV patients.
  • Cardiovascular disease is a leading cause of mortality in the HIV-infected population.
  • Understanding treatment-related metabolic effects is crucial for patient outcomes.

Purpose:

  • To evaluate the impact of nevirapine on lipid profiles, specifically HDL-c levels.
  • To investigate the association between nevirapine use and cardiovascular risk in HIV patients.
  • To highlight the role of apolipoprotein A1 in nevirapine's metabolic effects.

Summary:

  • Nevirapine has demonstrated superiority in managing HDL-c lipid disorders compared to other ART combinations.
  • This protective effect is attributed to nevirapine's role in enhancing apolipoprotein A1 production.
  • International cohort studies indicate a potentially low cardiovascular morbidity risk associated with nevirapine exposure.

Impact:

  • Nevirapine's favorable lipid profile and low cardiovascular risk profile should be considered in ART selection.
  • This is particularly relevant for initiating treatment in patients with pre-existing cardiovascular risk factors.
  • Nevirapine may be a suitable option for substituting existing effective triple therapies.

More Related Videos

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Cellular Redox Profiling Using High-content Microscopy11:37

Cellular Redox Profiling Using High-content Microscopy

Published on: May 14, 2017

Related Concept Videos

Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Retroviruses02:33

Retroviruses

Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...